NASDAQ:NERV Minerva Neurosciences Q1 2026 Earnings Report $4.48 -0.10 (-2.18%) As of 02:04 PM Eastern ProfileEarnings HistoryForecast Minerva Neurosciences EPS ResultsActual EPS-$0.17Consensus EPS -$0.13Beat/MissMissed by -$0.04One Year Ago EPSN/AMinerva Neurosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AMinerva Neurosciences Announcement DetailsQuarterQ1 2026Date5/5/2026TimeBefore Market OpensConference Call DateTuesday, May 5, 2026Conference Call Time8:00AM ETUpcoming EarningsMinerva Neurosciences' Q3 2026 earnings is estimated for Wednesday, November 4, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Minerva Neurosciences Earnings HeadlinesHC Wainwright Has Negative Estimate for NERV Q3 EarningsAugust 14 at 1:43 AM | americanbankingnews.comWall Street Zen Upgrades Minerva Neurosciences (NASDAQ:NERV) to HoldAugust 8, 2026 | americanbankingnews.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.August 17 at 1:00 AM | InvestorPlace (Ad)Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business UpdatesAugust 7, 2026 | globenewswire.comMinerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline ProgramsJune 1, 2026 | globenewswire.comMinerva Neurosciences Launches ATM Offering to Fund TrialMay 27, 2026 | tipranks.comSee More Minerva Neurosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Minerva Neurosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Minerva Neurosciences and other key companies, straight to your email. Email Address About Minerva NeurosciencesMinerva Neurosciences (NASDAQ:NERV). is a clinical‐stage biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. The company’s research and development efforts are directed toward addressing unmet needs in psychiatric and neurological conditions, leveraging its expertise in neuropharmacology and receptor modulation. Minerva’s goal is to bring forward differentiated molecules that can offer improved efficacy and safety profiles compared to existing treatments. The company’s most advanced programs include roluperidone (formerly MIN-101), which has been investigated for the treatment of negative symptoms of schizophrenia, and MIN-117, a novel serotonergic agent being evaluated in major depressive disorder. Roluperidone is designed to modulate a combination of sigma and adrenergic receptors without dopaminergic activity, potentially reducing side effects associated with traditional antipsychotics. MIN-117 targets multiple serotonin receptor subtypes and the serotonin transporter, with the aim of providing antidepressant benefit while minimizing common adverse events linked to selective serotonin reuptake inhibitors. Headquartered in Cambridge, Massachusetts, Minerva Neurosciences operates research facilities in the United States and collaborates with academic partners and contract research organizations worldwide to advance its pipeline through clinical development. The company was founded in 2013 and has since progressed multiple candidates through Phase 1 and Phase 2 trials. Under the leadership of President and Chief Executive Officer Vipin K. Garg, Minerva continues to explore strategic partnerships and funding opportunities to support late‐stage clinical trials and, ultimately, regulatory submissions.View Minerva Neurosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Birkenstock Beats the Skeptics—But Not on EPSThese 5 Dividend Stocks Show Why Income Investing Still MattersThe Quantum Race Is Heating Up—And 2 Small Players Stand OutMarketBeat Week in Review – 08/10 - 08/14Applied Materials Beat Everything but Wall Street’s Expectations for MarginsLooking Beyond CrowdStrike? 3 AI Security Stocks Stand Out5 Recession-Proof Stocks Hiding in Cardboard Boxes Upcoming Earnings Home Depot (8/18/2026)Medtronic (8/18/2026)Keysight Technologies (8/18/2026)Lowe's Companies (8/19/2026)TJX Companies (8/19/2026)Target (8/19/2026)Analog Devices (8/19/2026)NetEase (8/20/2026)Alibaba Group (8/20/2026)Ross Stores (8/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
